DNA fusion gene vaccines.
DNA vaccines are versatile and safe, but limited immunogenicity has prevented their use in the clinical setting. Experimentally, immunogenicity may be enhanced by the use of new delivery technologies, by coadministration of cytokines and pathogen-associated molecular patterns, or by fusion of antigens into molecular domains that enhance antigen presentation. More specifically, the immunogenicity of DNA vaccines may benefit from increased protein synthesis, increased T-cell help and MHC class I presentation, and the addition of a range of specific cytokines and pathogen-associated molecular patterns that increase activation of the innate immune system. Importantly, viral-vectored vaccines that act through the induction of one or more of these factors also may benefit from cytokine coadministration and increased antigen presentation. In order to increase immunogenicity to the level achieved with viral-vectored vaccines, various synergistic components may need to be incorporated into DNA vaccines. From the perspective of the future clinical use of DNA vaccines, it has been suggested that antigen presentation should be improved and cytokine coadministration attempted. However, even with these modifications, it is likely that the primary use of DNA vaccines may be as primers for viral-vectored vaccines, rather than as single agents. This review discusses the approaches used to enhance DNA vaccine immunogenicity, with a primary focus on fusion strategies that enhance antigen presentation.
The Panum Institute, Copenhagen N, Denmark. pholst@sund.ku.dk
Peter Johannes
PJ
Holst
Maria Rosaria
MR
Bassi
Allan Randrup
AR
Thomsen
Jan Pravsgaard
JP
Christensen
D017951:Antigen Presentation / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D050939:Gene Fusion; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D019444:Vaccines, DNA / Q000737:chemistry / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D019444:Vaccines, DNA